---
title: "Belgium's Agomab Therapeutics raises $200 million in US IPO"
description: "Agomab Therapeutics has raised $200 million in its U.S. initial public offering, the company said on Thursday, setting the stage for a Nasdaq debut by the biopharmaceutical firm."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275051300.md"
published_at: "2026-02-06T00:30:18.000Z"
---

# Belgium's Agomab Therapeutics raises $200 million in US IPO

> Agomab Therapeutics has raised $200 million in its U.S. initial public offering, the company said on Thursday, setting the stage for a Nasdaq debut by the biopharmaceutical firm.

Agomab Therapeutics has raised $200 million in its U.S. initial public offering, the company said on Thursday, setting the stage for a Nasdaq debut by the biopharmaceutical firm.

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [APGE.US - Apogee Therapeutic](https://longbridge.com/en/quote/APGE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Apogee Therapeutics 的首席執行官出售了 20,000 股股票 | 邁克爾·托馬斯·亨德森（Michael Thomas Henderson），Apogee Therapeutics 的首席執行官，於 2026 年 2 月 11 日根據 10b5-1 交易計劃出售了 20,000 股普通股，總金額為 1,2 | [Link](https://longbridge.com/en/news/275958084.md) |
| 分析師的判決：18 位專家眼中的安進 | 安進（NASDAQ:AMGN）在過去三個月內獲得了 18 位分析師的混合評級，平均 12 個月目標價為 350.61 美元，比之前的目標上漲了 6.93%。分析師們提高了他們的評級和目標價，其中富國銀行和派珀·桑德勒等公司的增幅尤為顯著。安 | [Link](https://longbridge.com/en/news/276494592.md) |
| BB Biotech 受益於市場環境的改善 | BB Biotech 報告稱，2025 年淨利潤為 5.78 億法郎，較 2024 年的 7600 萬法郎大幅增長。僅第四季度就貢獻了 4.72 億法郎，這得益於積極的投資組合管理和對 Amicus Therapeutics 和 Nuval | [Link](https://longbridge.com/en/news/276427224.md) |
| 阿伯丁集團有限公司在 Tectonic Therapeutic, Inc. $TECX 中建立了價值 559 萬美元的頭寸 | 阿伯丁集團（Aberdeen Group plc）在 Tectonic Therapeutic, Inc.（納斯達克代碼：TECX）中獲得了約 559 萬美元的新頭寸，在第三季度購買了 356,176 股。這項投資約佔 Tectonic 股 | [Link](https://longbridge.com/en/news/276507461.md) |
| 關鍵事實：Candel Therapeutics 獲得 1 億美元資金；計劃推出新藥 | Candel Therapeutics 已與 RTW Investments 達成了一項 1 億美元的融資協議，用於其治療藥物 Aglatimagene Besadenovec，待 FDA 批准，且根據美國銷售情況支付版税。Candel T | [Link](https://longbridge.com/en/news/276481541.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.